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The Vaccine Adverse Event Reporting System (VAERS) received thousands of 
reports of adverse events that occurred after vaccine administrations from the post-
marketing vaccine safety surveillance. However, the causality between vaccines and 
reported adverse events cannot be taken for granted. In this report several data mining 
methods were applied to VAERS database that is coded in MedDRA terms to discover 
possible associations between vaccines and adverse events. Efforts were devoted to 
identify events that are reported more frequently after administering one vaccine than 
other vaccines using the following data mining techniques: relative ratio (RR), statistical 
significance (LogP), proportional reporting ratio (P RR), and screened P RR (SPRR).  
The vaccine-event combinations that ranked top  in each method varied 
substantially among the methods. RR and PRR gave excessive weight to small counts of 
vaccine-event pa irs, but SPRR was able to correct this weakness. There are only 33 
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vaccine-event pairs that were shared among the top 1,000 ranked in each method. 
Evaluating the properties of these data mining methods and exploring other methods will 
help improve vaccine safety surveillance. 
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It is accepted that the safety profile of therapeutic products (drugs, vaccines, 
medical devices) cannot be fully accessed before the products are approved for marketing 
due to the limitations of clinical trials. Therefore it is important for pharmaceutical 
companies and regulatory agencies to monitor and collect the side effects of products 
after the products are licensed for use in markets. A few spontaneous adverse event 
reporting systems have been initiated to collect post-marketing safety surveillance data in 
the United States.1 The Vaccine Adverse Event Reporting System (VAERS) is one such 
system co-sponsored by the Food and Drug Administration (FDA) and the Centers for 
Disease Control and Prevention (CDC) to monitor vaccine safety.2  
VAERS receives around 30,000 reports annually from health care providers, 
manufacturers and vaccine recipients.2 Each report describes one or more adverse events 
that occur after the administration of a certain vaccine, but VAERS does not determine its 
causality. Some of these events may occur just coincidentally following vaccination, 
while others may truly be caused by vaccination (e.g., injection site reaction). Signs and 
symptoms of reported adverse events on VAERS report used to be coded in the FDA's 
Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) from 
November 1990 until January 2007. Since January 2007 the VAERS coding system was 
converted to an international coding system Medical Dictionary for Regulatory Activities 
(MedDRA). There are more than 17,000 Preferred Term codes in the MedDRA system 
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that describe adverse events, while COSTART system is only comprised of 5,817 codes. 
Therefore the MedDRA system is not only standardized for international use, it is also 
able to code medical terms in a more exacting manner than the COSTART system 
design. 
One interest in the analysis of VAERS data focuses on looking for patterns to 
detect if certain adverse events are plausibly linked to certain vaccines. However, 
spontaneous reporting systems such as VAERS do have some limitations including 
reporting bias (underreporting, differential reporting or stimulated reporting), inconsistent 
data quality, absence of an unvaccinated control group and inadequate denominator data 
(doses administrated or subjects vaccinated). The lack of control group and denominator 
data often limit the ability of traditional methods of signa l detection and risk analysis, 
which require a controlled study or background rates.3  
To address these limitations, various data mining techniques have been proposed 
to help detect potential safety concerns in the spontaneous reporting system. Data mining,  
defined as the process of looking for relationships and patterns from large datasets by 
combining methods from statistics and artificial intelligence with database management, 
is an increasingly important tool with great potential to extract previously unknown and 
potentially useful information, which then usually facilitates decision making4.  
In the situation of lack of a true unvaccinated control, data mining methods 
manage to use all other vaccines as a quasi-control group to analyze the vaccine of 
interest. Data mining cannot remove reporting bias, but can specify different proportions 
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of adverse events for each vaccine, where higher safety risks for certain vaccines can be 
detected but absolute ratios are not calculated.3  
In 2005 Banks et al. compared several data mining methods on the VAERS 
database when the adverse events were still coded in COSTART terms. Because the 
VAERS database had converted its data to the more accurate and comprehensive 
MedDRA coding system in 2007, it is of interest to see if how these data mining methods 
would behave in the new system of MedDRA code. The objective here is not to judge the 
vaccine-adverse event causality, as it’s more complicated to interpret than only using data 
mining and statistical methods. Rather, the goal is to determine whether these methods 







The information of each report to VAERS is divided to three pieces and stored 
separately: the patient’s demographic information, the vaccine administration record and 
the adverse event coded in MedDRA. For the purpose of this analysis, three datasets were 
assembled; only reports with complete records of vaccine and MedDRA information 
were kept. Then the pre-processed database was transformed to a contingency table with 
vaccines in rows and the MedDRAs in columns. Each cell Nij contains the number of the 
MedDRA of that column reported after the vaccine of the corresponding row. 
Though occasionally one single report would report multiple MedDRAs, the 
effect of this case tends to be small, thus we assume that separate events are reported 
independently. In this report, a few main data mining techniques that have been explored 
within FDA will be applied to the newest VAERS data.  
RELATIVE RISK (RR) 
The method of relative risk in evaluating Nij is comprised of two steps, the first 
step is to define a baseline or null hypothesis frequency Eij, and the second step is then to 
compare the observed Nij to the baseline frequency Eij. The null hypothesis assumes that 
the vaccines and the MedDRAs are independent, though it’s certainly accepted that they 
are associated in the system; the objective is not to test their independence, but to test if 
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there is any Nij surprisingly larger than the baseline Eij This association is of interest.6 
Assuming the MedDRAs are independent of the vaccines would give: 
                                                𝐸𝑖𝑗 =
𝑁𝑖 .𝑁.𝑗
𝑁 . .
                                                             
(1)                                        
This simplest criterion is defined on the ratio 
                                                         𝑅𝑅𝑖𝑗 = 𝑁𝑖𝑗 𝐸𝑖𝑗⁄                                                          
(2) 
The relative risk evaluation is easy to interpret, if a pair of vaccines and MedDRA 
has been observed thousands of times more than expected, then we can conclude that 
there is plausibly an assoc iation between this MedDRA and this vaccine.  
STATISTICAL SIGNIFICANCE (SS) 
A statistical test criterion for testing the null hypothesis that 𝐸�𝑁𝑖𝑗� =𝐸𝑖𝑗  is 
defined as  
𝐿𝑜𝑔𝑃𝑖𝑗 = −log (Pr�𝑋 ≥ 𝑁𝑖𝑗�), where X ~ Poisson (𝐸𝑖𝑗).  
The purpose is not to test the null hypothesis, but use the test statistics or degree 
of the significance to rank the vaccine-MedDRA assoc iation.  
In the case of 𝑁𝑖𝑗 ≫ 𝐸𝑖𝑗, 𝐿𝑜𝑔𝑃𝑖𝑗 could be too large for computation
5. Thus, the 
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(3) 
PROPORTIONAL RELATIVE RISK (PRR) 
The proportional relative risk measures the proportion of MedDRAj reported after 
vaccine i is divided by the proportion of MedDRAj reported after all other vaccines.3 A 
large PRR indicates a specific vaccine - MedDRA pair has been disproportionally 
reported after that vaccine, compared to other vaccines. 
                                       𝑃𝑅𝑅𝑖𝑗 =
𝑁𝑖𝑗/𝑁𝑖 .
(𝑁 .𝑗−𝑁𝑖𝑗 )/(𝑁..−𝑁𝑖 . )
                                               
(4) 
PRR is also an intuitive measure in the absence of exposure data, but it has a few 
shortcomings. PRR would be infinite if the MedDRA is only reported after one vaccine 
but not  others; in this case 𝑁.𝑗 − 𝑁𝑖𝑗 = 0. Also if 𝑁𝑖𝑗 is small, the generated signal can 
have large variance. 
SCREENED PROPORTIONAL REPORTING RATIO (SPRR) 
In the method o f P RR, Evans et al. proposed to determine whether or not there is a 
signal, and its strength, is based on three pieces of information: the PRR, value of chi-
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squared and the absolute number of reports. The chi-squared test is one degree of 
freedom of Yates correction to measure statistical association.6 The Yates correction is a 
continuity adjustment to improve the accuracy of chi-squared approximation to the 
distribution of  Pearson’s test for independence in a contingency table.3 They suggested 
defining a signal as PRR ≥ 2, Yates-corrected chi-square ≥ 4, and 𝑁𝑖𝑗 ≥ 3. The formula 
for the Yates-corrected chi-square is 
         Yates-corrected X2 = ∑(�𝑁𝑖𝑗 − 𝐸𝑖𝑗 � − 0.5)2 /𝐸𝑖𝑗                  
(5) 
𝐸𝑖𝑗 has the same definition as defined in Eq. (1).  
In the results that follow, all calculations were performed using a standard 






Adverse events reported to VAERS system in the year of 2010 were analyzed in 
this report. There are 31,651 pieces of patients’ demographic records, 49,736 pieces of 
vaccine administration records of these patients and 40,102 pieces of reported safety 
records in the database. Assembling these three datasets together generated 56,258 
vaccine-MedDRA pairs that were repor ted in the system. This indicates that a single 
report may contain more than one vaccine and may report multiple adverse events. The 
data on 68 vaccines and 2,143 unique MedDRAs were reported, which can be considered 
to be a contingency table with 68 rows (vaccines) and 2,143 columns (MedDRAs).  
A frequency plot as shown on Figure 1 indicates that 6,329 vaccine-MedDRA 
pairs each occurred only once in VAERS. The pairs that were reported most frequently 
(far right  of graph) are injection site erythema that usually occurred after many vaccines. 
The most frequently reported vaccine-MedDRA pairs in VAERS of 2010 are listed in 
Table 1. 
Table 1:  The 10 most frequently reported vaccine-MedDRA pairs in VAERS. 









Vaccine VARCEL MMR Flu (10-11) PPV TDAP 
Count 908 563 530 496 463 





Vaccine DTAP Flu (10-11) HEPA DTAP|PV PPV 




Figure 1: Frequency of occurrence of vaccine-MedDRA pairs for 56268 pairs that 
occurred at least once in the VAERS system. 6329 vaccine-MedDRA pairs were reported 
only once (far left of graph), the pairs that were reported more frequently (far right of 
graph) are injection site erythema that usually occurred after many vaccines.   
RELATIVE RISK  
The calculated relative risk ratios from formula (2) ranged from 0.039 to 7032.25. 
There are 10 vaccine-MedDRA pairs with a relative risk that exceeded 1000, as listed in 
Table 2. However, the actual occurrences 𝑁𝑖𝑗 that generate large RR scores of these 10 







Table 2: Vaccine-MedDRA pairs appearing in the top 10 ranked by RR score 





infective Heat therapy 
Vaccine HBPV RUB DTPPHIB DTAPH DTPPHIB 
RR 7032.25 3125.44 2678.95 1654.65 1607.37 
Count  1 1 1 1 1 









Vaccine MEA HBHEPB HPV DT OPV 
RR 1406.45 1250.18 1125.16 1125.16 1081.88 
Count  1 1 1 1 1 
PROPORTIONAL REPORTING RATIO 
According to the formula (4), a MedDRA that is reported only after one vaccine 
but not  others would lead to an infinite PRR score, such pairs were omitted from the 
calculation of P RR. The rest of the pairs produced P RR scores ranging from 0.038 to 
14,063.5. There are 13 vaccine-MedDRA pairs with a relative risk that exceed 1,000; the 
top 10 scores are listed in the Table 3.  
Table 3: Vaccine-MedDRA pairs appearing in the top 10 ranked by P RR score 







fibrosis Heat therapy 
Vaccine HBPV DTPPHIB DTAPH OPV DTPPHIB 
PRR 14063.5 4017.93 3308.29 2162.77 2008.96 
Count 1 1 1 1 1 









Vaccine HBHEPB 6VAX-F HBHEPB HPV DT 
PRR 1874.77 1278.09 1249.84 1125.16 1081.88 
Count 1 1 1 1 1 
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Comparing Table 3 to Table 2, most of the pairs that ranked in the top 10 by RR 
method also appear in the top 10 list of PRR method, and all of them have a count of 1.  
Figur e 2 displays the natural logarithm of the RR signa l versus the natural 
logarithm of the PRR signal. The two evaluation methods are in good agreement for most 
of the vaccine-MedDRA pairs, except for a few pairs that the red arrow points to. These 
are the pairs that have large P RR scores for 𝑁𝑖𝑗 = 1, confirming that P RR gives excessive 
weight to singleton pairs, and thus it is highly subject to sampling variance3. 
 
 
Figure 2: Scatterplot of log RR vs log PRR. The two methods are in good agreement 
except for a few points (arrow) that consist of vaccine-MedDRA pairs for which only one 





LogP of 25 vaccine-MedDRA pairs could not be obtained in the computation of 
LogP, indicating that 𝑁 ≫ 𝐸 for these pairs. So the approximation method as described 
in formula (3) was applied when 𝑁− 𝐸 > 5. Table 4 lists the top 10 vaccine-MedDRA 
pa irs that were ranked by LogP. 
Table 4: Vaccine-MedDRA pairs appearing in the top 10 ranked by LogP score 
MedDRA  Herpes Zoster 
Blood amylase 
increased Cry ing Syncope Cellu lit is 
Vaccine VARZOS MMR DTAP|PVHIB HPV4 PPV 
LogP 82.38 71.52 56.24 53.39 52.19 
Count  94 86 95 124 158 





Vaccine MMR FLUN(H1N1) FLUN FLUHD(10-11) VARCEL 
LogP 49.56 46.03 44.15 39.67 37.40 
Count  59 43 52 87 62 
In contrast with the RR and PRR methods, the top pairs chosen by the LogP 
method were reported frequently in the system.  
SCREENED PROPORTIONAL REPORTING RATIO  
 The screened version of PRR tends to repair the shortcoming of the PRR method  
mentioned above. The SPRR dropped the pairs with 𝑁𝑖𝑗 < 3, and also required the pa irs 
to be statistically significant and have a PRR score ≥ 2. There are 808 vaccine-MedDRA 





  Table 5:Vaccine-MedDRA pairs appearing in the top 10 ranked by SPRR score 
MedDRA  Mumps Uveitis  Blood amylase increased Blood amylase Myopericarditis 
Vaccine MMR HEP MMR MRR SMALL 
PRR 953.57 800.92 694.98 549.52 534.50 
Count  59 22 86 34 3 











Vaccine SMALL MMR SMALL HPV4 HIBV 
PRR 237.55 226.27 195.98 189.58 189.49 
Count  4 14 11 12 4 
 
Figure 3 shows a plot of natural logarithm of the RR score against the natural 
logarithm of the screened PRR score. In comparison with Figure 2, all the points have a 
logarithm score ≥ 0.693 (ln2), as SPRR only keep pairs with PRR score ≥ 2. The points 
with extremely large RR scores and PRR scores disappear from the figure, as they 
correspond to cells with 𝑁𝑖𝑗 = 1  or where Yates-corrected X







Figure 3: Scatterplot of ln RR vs ln SPRR. The points with extremely small scores and 
extremely large scores disappear from the figure in comparison with Figure 2, since 
SPRR only include cells for which 𝑁𝑖𝑗 ≥ 3, PRR ≥ 2 and Yates-corrected X2 is 
statistically significant.  
 
Table 6 shows some statistics for the 33 pairs that ranked in the top 1,000 pairs by 
three criteria: SS, LogP and SPRR. The fact that three sets of 1,000 pairs only have 33 in 
common indicates that there are real differences among those three selections. Table 4 
shows the frequency of each pa ir and the rankings  of this pa ir by these selection methods , 
the ranking b y the PRR score are also listed for reference. It is interesting to see that these 
pairs also ranked among top 1,000 by the PRR method, and the rankings by the method of 
RR are closer to the method of PRR, while the rankings produced by SPRR are closer to 
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the ones of LogP. In addition, the intersections of pairs selected by these three criteria 






Table 6. Pairs appearing in the top 1,000 when ranked by all four methods 









6VAX-F Cry ing 5 995 824 87 153 
ANTH Echocardiogram abnormal 5 697 469 42 118 
ANTH Echocardiogram normal 9 664 436 39 65 
DPP Cry ing 4 887 818 84 222 
DTAPHEPBIP Abnormal faeces 3 769 594 51 300 
DTAPIPVHIB Culture urine 3 884 546 49 349 
FLUHD(10-11 Blood creatinine increased 3 761 439 40 286 
FLUN(10-11) Ep istaxis 7 807 595 52 117 
FLUN(10-11) Cheilitis 4 754 529 48 175 
FLUN(H1N1) Underdose 14 635 118 13 37 
FLUN(H1N1) Drug admin istration error 43 732 242 23 7 
FLUN Contraindication to vaccination 15 661 433 38 34 
HEP Drug ineffective 4 709 123 14 161 
HEP Uveitis  22 634 17 2 20 
HIBV Haemophilus test positive 4 556 87 10 139 
PNC Pneumococcal bacteraemia 3 708 246 26 263 
PNC Chronic obstructive pulmonary  4 882 470 43 217 
ROT Somnolence 3 421 361 31 174 
ROTH1 Incorrect route of drug 
administration 
9 760 614 53 76 
ROTH1 Culture stool negative 3 643 474 45 235 
ROTH1 Intussusception 5 639 471 44 106 
ROTHB5 Regurgitation 5 657 245 25 112 
ROTHB5 Infantile  spitting up 5 759 385 32 128 
ROTHB5 Rotavirus infection  12 770 432 37 46 
ROTHB5 Culture stool positive 7 883 555 50 129 
SMALL Electrocardiogram abnormal 5 355 220 20 82 
SMALL Pericardit is 3 303 189 18 145 
SMALL Myopericarditis 3 141 33 5 105 
SMALL Myocarditis 4 216 67 6 86 
SMALL Acute myocardial infarction 4 230 91 11 89 
SMALL Blood creatine phosphokinase 
M 
3 394 244 24 165 
SMALL Echocardiogram abnormal 11 226 84 8 31 







Significant effort has been devoted to improving the efficiency of adverse event 
reports using data mining methods in recent years. An Empirical Bayes geometric mean 
(EBGM) has been proposed by DuMouchel5, and has been proposed to be a metric to 
measure the drug and adverse event association in the spontaneous reporting system. This 
method is currently adopted by FDA and has been incorporated in a software package 
called MGPS (Multi-Item Gamma Poisson Shrinker) in collaboration by DuMouchel, 
Lincoln Technologies and GlaxoSmithKline1. The EBGM method assumes that the 
counts 𝑁𝑖𝑗 in each cell are random variables from Poisson distribution with unknown 
means 𝜇𝑖𝑗 where 𝜇𝑖𝑗 are random variables from a common distribution. This common 
distribution is usually taken to be a mixture of two gamma distributions. The EBGM 
method has been shown to shrink the estimates of reporting ratio parameters in the 
Poisson distributions towards each other, thus reducing the effect of sampling variation in 
the data; this method also preserves the interpretability of the parameters and the 
estimates. But this approach is computationally intensive, thus due to the limited 
computational resources available in this report, this method was not studied.  
Several data mining methods have been applied to the VAERS database when the 
system was coded in COSTART terms. In this report these data mining methods were 
applied to the new VAERS data where accurate adverse event descriptions in MedDRA 
terms were used. The qualitative features of the comparisons are as follows: Metrics 
based on the RR seem to be too favorable for cells with small counts. This may be 
improved by requiring a minimum value of N to be included into the analysis, such 
as 𝑁 ≥ 5, but the cutoff is arbitrary.5 The raw P RR has the same prob lem with small 
counts, such that singleton cases tend to generate extremely large PRR scores. In 
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comparison with PRR, the SPRR has a significant improvement than PRR; moreover, 
previous studies has pointed out that SP RR is competitive with the EBGM method.3 
Determining which method is best will need additional analysis that focuses on true 
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